Abstract
Non-Hodgkin Lymphoma is a heterogeneous group of lymphoid malignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and potentially cure. Even in indolent lymphomas, ASCT shows a definite improvement in progression-free survival, although no improvement in overall survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Swerdlow AJ (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, France
http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.asp
Gyan E, Foussard C, Bertrand P et al (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113(5):995–1001
Lenz G, Dreyling M, Schiegnitz E et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104(9):2667–2674
Freeman BJ, Roberts MS, Vogler CA et al (1999) Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood 94(6):2142–2150
Apostolidis J, Gupta RK, Grenzelias D et al (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18(3):527–536
Brice P, Simon D, Bouabdallah R et al (2000) High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11(12):1585–1590
Grigg AP, Stone J, Milner AD et al (2010) Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma 51(4):641–649
Bierman PJ, Vose JM, Anderson JR et al (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 15(2):445–450
Cao TM, Horning S, Negrin RS et al (2001) High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 7(5):294–301
Schouten HC, Qian W, Kvaloy S et al (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918–3927
Montoto S, Canals C, Rohatiner AZ et al (2007) Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 21(11):2324–2331
Freedman AS, Gribben JG, Neuberg D et al (1996) High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88(7):2780–2786
Horning SJ, Negrin RS, Hoppe RT et al (2001) High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97(2):404–409
Ladetto M, Corradini P, Vallet S et al (2002) High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100(5):1559–1565
Deconinck E, Foussard C, Milpied N et al (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105(10):3817–3823
Sebban C, Mounier N, Brousse N et al (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 108(8):2540–2544
Hamadani M, Benson DM Jr, Lin TS et al (2008) High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 81(6):425–431
Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417–1423
Sebban C, Brice P, Delarue R et al (2008) Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26(21):3614–3620
Witzens-Harig M, Dreger P (2010) Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 51(6):967–974
Sehn LH, Donaldson J, Filewich A et al (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109(10):4171–4173
Greb A, Bohlius J, Trelle S et al (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. Cancer Treat Rev 33(4):338–346
Vitolo U, Chiappella A, Angelucci E et al (2009) Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 94(9):1250–1258
Glass B, Ziepert M, Reiser M et al (2010) High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol 21(11):2255–2261
Stiff PJ, Unger JM, Cook J, Constine LS, Couban S, Shea TC, Winter JN, Miller TP, Tubbs RR, Marcellus DC, Friedberg JW, Barton K, Mills GM, LeBlanc ML, Rimsa L, Forman SJ, Fisher RI (2011) Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP +/− R for eight cycles to CHOP +/− R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 29:8001, Meeting Abstract
Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333(23):1540–1545
Buadi FK, Micallef IN, Ansell SM et al (2006) Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant 37(11):1017–1022
Jantunen E, Canals C, Rambaldi A et al (2008) Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 93(12):1837–1842
Tam CS, Bassett R, Ledesma C et al (2009) Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144–4152
Geisler CH, Kolstad A, Laurell A et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687–2693
Dreger P, Rieger M, Seyfarth B et al (2007) Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 92(1):42–49
Romaguera JE, Fayad L, Rodriguez MA et al (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013–7023
Jantunen E, Canals C, Attal M et al (2011) Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 23:166–171
Sweetenham JW. Highly aggressive lymphomas in adults. Hematology/oncology clinics of North America 2008; 22(5): 965–78, ix.
Jost LM, Jacky E, Dommann-Scherrer C et al (1995) Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann Oncol 6(5):445–451
Sweetenham JW, Pearce R, Taghipour G et al (1996) Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma–outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14(9):2465–2472
Song KW, Barnett MJ, Gascoyne RD et al (2006) Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 133(6):634–637
van Imhoff GW, van der Holt B, MacKenzie MA et al (2005) Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 19(6):945–952
Hosing C, Champlin RE (2011) Stem-cell transplantation in T-cell non-Hodgkin’s lymphomas. Ann Oncol 22:1471–1477
Coiffier B, Brousse N, Peuchmaur M et al (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol 1(1):45–50
Rodriguez J, Conde E, Gutierrez A et al (2007) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18(4):652–657
Duarte RF, Schmitz N, Servitje O et al (2008) Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 41(7):597–604
Reimer P, Rudiger T, Geissinger E et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106–113
Mercadal S, Briones J, Xicoy B et al (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958–963
Rodriguez J, Conde E, Gutierrez A et al (2007) Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 78(4):290–296
Feyler S, Prince HM, Pearce R et al (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 40(5):443–450
Sieniawski M, Angamuthu N, Boyd K et al (2010) Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 115(18):3664–3670
Al-Toma A, Verbeek WH, Hadithi M et al (2007) Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 56(10):1373–1378
Gale J, Simmonds PD, Mead GM et al (2000) Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 18(4):795–803
Jantunen E, Juvonen E, Wiklund T et al (2003) High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 44(12):2163–2164
Rongey C, Micallef I, Smyrk T et al (2006) Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant. Dig Dis Sci 51(6):1082–1086
Al-toma A, Verbeek WH, Mulder CJ (2007) The management of complicated celiac disease. Dig Dis 25(3):230–236
Bishton MJ, Haynes AP (2007) Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 136(1):111–113
Bigler RD, Crilley P, Micaily B et al (1991) Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 7(2):133–137
Olavarria E, Child F, Woolford A et al (2001) T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 114(3):624–631
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Songdej, N., Winer, E.S. (2013). Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphomas. In: Quesenberry, P., Castillo, J. (eds) Non-Hodgkin Lymphoma. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5851-7_14
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5851-7_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5850-0
Online ISBN: 978-1-4614-5851-7
eBook Packages: MedicineMedicine (R0)